Kaitlyn D’Onofrio

DocwireNews

This week, the DocWire New rheumatology section had a special focus on COVID-19. In this edition, read about a tocilizumab trial, immunosuppressive agents in rheumatic COVID-19 patients, canakinumab in &ldquo;cytokine storm&rdquo; prevention, and whether rheumatic diseases affect COVID-19.An Italian study <a href="https://www.docwirenews.com/docwire-pick/rheumatology-picks/roches-tocilizumab-does-not-improve-covid-19-pneumonia-more-research-underway/">did not observe a benefit for early COVID-19 pneumonia patients</a> who were given tocilizumab, Roche&rsquo;s rheumatoid arthritis drug marketed as Actemra. The study, authorized by the Italian Medicines Agency (Aifa), was stopped early. However, Roche is still reportedly moving ahead with its own phase III clinical trial of the drug. The Italian trial, a collaborative effort of 24 centers, randomized 126 patients initially; final analyses included 123, after three patients withdrew consent. The rate of two-week aggravations was similar between those who received tocilizumab versus those who received standard therapy (28.3% vs. 27.0%), as were rates of those who required intensive care (10.0% vs. 7.9%) and 30-day mortality (3.3% vs. 3.2%).Researchers examined outcomes associated with <a href="https://www.docwirenews.com/docwire-pick/rheumatology-picks/what-does-covid-19-look-like-in-patients-taking-immunosuppressive-agents/">COVID-19 among patients with underlying rheumatic diseases</a> taking immunosuppressive agents. The study authors concluded that, &ldquo;[Rheumatic disease] patients are susceptible to COVID-19. Various [disease-modifying antirheumatic drugs] may affect the viral process differently. Patients on etanercept, [hydroxychloroquine], or tocilizumab may run a mild course of the viral illness. Rituximab or secukinumab could worsen the viral disease and its related complications.&rdquo; They called for larger studies in the future.A Texas-based study is enrolling patients in its <a href="https://www.docwirenews.com/docwire-pick/rheumatology-picks/canakinumab-to-be-tested-for-preventing-covid-19-cytokine-storm-in-phase-iii-clinical/">phase 3 clinical trial of arthritis drug canakinumab</a> to see if it effectively prevents cytokine release syndrome in COVID-19 patients with pneumonia. The interleukin-1 (IL-1) blocker is being tested to see if combination canakinumab and standard-of-care treatment increases survival without invasive ventilation in patients with COVID-19 pneumonia. A &ldquo;cytokine storm&rdquo; has been associated with the virus. This refers to COVID-19 patients who appear to be getting better, then rapidly deteriorate. This happens when the body is no longer fighting off the virus but instead starts attacking its own immune system. Cytokine storms are seen in patients with rheumatic diseases as well as cancer.An Italian study recently found that <a href="https://www.docwirenews.com/docwire-pick/rheumatology-picks/do-rheumatic-diseases-affect-covid-19-its-complicated-according-to-researchers/">rheumatic and musculoskeletal diseases themselves may not be what affects COVID-19</a>, but a patient&rsquo;s age and comorbidities. &ldquo;Based on the current findings, pre-existing systemic autoimmune disease and ongoing immunosuppressive treatment do not appear to represent the most important risk factors for SARS-CoV-2 infection and for its final outcome. Instead, mortality seems to be associated more with older age and the presence of comorbidities rather than the degree of pharmacological immunosuppression,&rdquo; the study authors concluded.

Jordana Jampel

Positive Preliminary Results From Phase 1 Trial of Dopaminergic Neuron Graft for Parkinson’s Disease

Dementia

Bradley Warady, MD

Joel M. Topf, MD, FACP

2025 Hume Award Winner Is Dedicated to Children’s Care

NKF Spring Clinical Meetings 2025

Distant Brain Metastases in Cutaneous Melanoma May Be Mitigated With Multiple Pathway Inhibitors

Melanoma

Latest News

Rheum Round-up, COVID-19 Edition: Arthritis Drug Trials, Rheumatic Disease And COVID-19

Rheumatology

This week, the DocWire New rheumatology section had a special focus on COVID-19. In this edition, read about a tocilizumab trial, immunosuppressive agents in rheumatic ...

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HER2 Breast Cancer

HR Breast Cancer

Triple-Negative Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe